查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1178502

脂质的全球市场 - 产业趋势与预测(～2030年)

Global Lipids Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 484 Pages | 商品交期: 请询问到货日

价格

全球脂质的市场规模，预计2023年～2030年记录8.4％大幅度的年复合成长率。

推动市场成长的主要原因，是医疗支出增加，诊断流程及技术的提高，影像技术的提高。

本报告提供全球脂质市场调查，市场促进因素和阻碍因素，机会和课题，各市场区隔、地区的市场明细，竞争情形，主要企业简介等彙整资讯。

目录

第1章 简介

第2章 市场区隔

第3章 摘要整理

第4章 重要考察

  • PESTEL分析
  • 波特的五力分析
  • 合併和收购
  • 专利分析
  • 药物治疗率:成熟各市场
  • 人口动态趋势:全部的发病率的影响
  • 主要的价格策略
  • 主要的病患註册策略
  • 价格分析
  • 临床试验
  • 产品的流通:各阶段
  • 开发平台分析
  • I期候补
  • I期/II候补
  • II期候补
  • III期候补

第5章 全球脂质市场:法律规范

  • 美国的法规
  • 欧洲的法规

第6章 市场概要

  • 促进因素
  • 阻碍因素
  • 机会
  • 课题

第7章 全球脂质市场:各类型

  • 概要
  • 天然脂质
  • 合成脂质

第8章 全球脂质市场:各脂质系统

  • 概要
  • 生理活性脂质
  • 聚合性脂质
  • 萤光脂质
  • 细菌脂质
  • 中性脂质
  • 头基改性脂质
  • 其他

第9章 全球脂质市场:各输送系统

  • 概要
  • 微脂体
  • 固体脂质奈米粒子
  • 奈米结构脂质电信业者
  • 传递体
  • 脂质体
  • 其他

第10章 全球脂质市场:各供给来源

  • 概要
  • 精製脂肪酸
  • 精炼油
  • 蛋黄
  • 大豆
  • 非基因改造大豆
  • 其他

第11章 全球脂质市场:各终端用户

  • 概要
  • 医药品产业
  • 生物科技产业
  • 化妆品产业
  • 学术研究机关
  • 其他

第12章 全球脂质市场:各销售管道

  • 概要
  • 直接竞标
  • 零售
  • 其他

第13章 全球脂质市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 西班牙
    • 法国
    • 瑞士
    • 比利时
    • 荷兰
    • 俄罗斯
    • 土耳其
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 印度
    • 澳洲
    • 新加坡
    • 泰国
    • 马来西亚
    • 印尼
    • 菲律宾
    • 其他亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美
  • 中东、非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 埃及
    • 以色列
    • 其他中东、非洲

第14章 全球脂质市场:企业形势

  • 企业占有率分析:世界
  • 企业占有率分析:北美
  • 企业占有率分析:欧洲
  • 企业占有率分析:亚太地区

第15章 SWOT分析

第16章 企业简介

  • BIONTECH SE.
  • MODERNA, INC.
  • PFIZER INC.
  • CARGILL, INCORPORATED.
  • KERRY.
  • ABITEC
  • ADMSIO
  • ALNYLAM PHARMACEUTICALS, INC.
  • BASF SE
  • CAYMAN CHEMICAL
  • CD BIOPARTCLES.
  • CHEMI S.P.A.
  • CORDENPHARMA INTERNATIONAL
  • CRODA INTERNATIONAL PLC.
  • CURIA GLOBAL, INC.
  • DSM
  • EVONIK INDUSTRIES AG
  • GATTEFOSSE
  • LIPOID GMBH
  • MATREYA, LLC
  • MERCK KGAA
  • NOF EUROPE GMBH
  • STEPAN COMPANY
  • TOKYO CHEMICAL INDUSTRY CO., LTD.
  • VAV LIFE SCIENCES PVT LTD

第17章 问卷调查

第18章 相关报告

The global lipids market is projected to register a substantial CAGR of 8.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Lipids Market, By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and others), Source (Eggyolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries, and Others), Distribution Channel (Direct Tender, Retail Sales and, Others), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherland, Russia, Switzerland, Turkey, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of global lipids market are:

Growing healthcare expenditure

Improved diagnostic processes and techniques

Improved imaging techniques

Market Players:

The key market players in the global lipids market are listed below:

Alnylam Pharmaceutical, Inc.

Croda International Plc.

Moderna Inc.

BioNTech SE.

Pfizer Inc.

Evonik Industries AG

Lipoid GmbH

Matreya LLC

VAV Life Sciences Pvt Ltd.

Curia Global Inc.

Cargill, Incorporated

Gattefosse

CD Bioparticles

Merck KGaA

NOF EUROPE GmbH

ABITEC

Cayman Chemical

CordenPharma International

CHEMI S.p.A.

DSM

BASF SE

Tokyo Chemical Industry Co., Ltd.

ADMSIO

Stepan Company

Kerry

TABLE OF CONTENTS

1 INTRODUCTION 45

  • 1.1 OBJECTIVES OF THE STUDY 45
  • 1.2 MARKET DEFINITION 45
  • 1.3 OVERVIEW OF GLOBAL LIPIDS MARKET 45
  • 1.4 LIMITATIONS 47
  • 1.5 MARKETS COVERED 47

2 MARKET SEGMENTATION 51

  • 2.1 MARKETS COVERED 51
  • 2.2 GEOGRAPHICAL SCOPE 52
  • 2.3 YEARS CONSIDERED FOR THE STUDY 53
  • 2.4 CURRENCY AND PRICING 53
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
  • 2.6 MULTIVARIATE MODELLING 57
  • 2.7 TYPE LIFELINE CURVE 57
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
  • 2.9 DBMR MARKET POSITION GRID 59
  • 2.10 MARKET END USER COVERAGE GRID 60
  • 2.11 VENDOR SHARE ANALYSIS 61
  • 2.12 SECONDARY SOURCES 62
  • 2.13 ASSUMPTIONS 62

3 EXECUTIVE SUMMARY 63

4 PREMIUM INSIGHTS 66

  • 4.1 PESTEL ANALYSIS 69
  • 4.2 PORTER'S FIVE FORCES 70
  • 4.3 MERGER AND ACQUISITION, GLOBAL LIPIDS MARKET 71
  • 4.4 PATENT ANALYSIS, GLOBAL LIPIDS MARKET 72
  • 4.5 DRUG TREATMENT RATE BY MATURED MARKETS 73
  • 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 74
  • 4.7 KEY PRICING STRATEGIES 75
  • 4.8 KEY PATIENT ENROLLMENT STRATEGIES 76
  • 4.9 PRICE ANALYSIS, GLOBAL LIPIDS MARKET 77
  • 4.10 GLOBAL LIPIDS MARKET, CLINICAL TRIALS 79
  • 4.11 GLOBAL LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE 80
  • 4.12 GLOBAL LIPIDS MARKET, PIPELINE ANALYSIS 81
  • 4.13 PHASE I CANDIDATES 81
  • 4.14 PHASE I/II CANDIDATES 82
  • 4.15 PHASE II CANDIDATES 83
  • 4.16 PHASE III CANDIDATES 84

5 GLOBAL LIPIDS MARKET, REGULATORY FRAMEWORK 85

  • 5.1 REGULATION IN THE U.S.: 85
  • 5.2 REGULATION IN EUROPE: 86

6 MARKET OVERVIEW 87

  • 6.1 DRIVERS 89
    • 6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES 89
    • 6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY 89
    • 6.1.3 INCREASE IN DRUG DEVELOPMENT 90
  • 6.2 RESTRAINTS 90
    • 6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS 90
    • 6.2.2 STRICT GOVERNMENT REGULATIONS 91
  • 6.3 OPPORTUNITIES 92
    • 6.3.1 RISE IN HEALTHCARE EXPENDITURE 92
    • 6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 92
  • 6.4 CHALLENGES 93
    • 6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION 93
    • 6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES 93

7 GLOBAL LIPIDS MARKET, BY TYPE 94

  • 7.1 OVERVIEW 95
  • 7.2 NATURAL LIPID 98
    • 7.2.1 UNSATURATED PHOSPHOLIPID 98
    • 7.2.2 HYDROGENATED PHOSPHOLIPID 99
    • 7.2.3 SPHINGOMYELIN 99
    • 7.2.4 GLYCEROLPHOSPHOCHOLINE 99
  • 7.3 SYNTHETIC LIPID 99
    • 7.3.1 PEGYLATED PHOSPHOLIPIDS 100
    • 7.3.2 PHOSPHATIDYLSERINE 100
    • 7.3.3 PHOSPHATIDYGLYCEROLS 100
    • 7.3.4 PHOSPHATIDYLETHANOLAMINE 100
    • 7.3.5 PHOSPHATIDYLCHOLINE 100
    • 7.3.6 PHOSPHATIDIC ACIDS 100

8 GLOBAL LIPIDS MARKET, BY LIPID SYSTEMS 101

  • 8.1 OVERVIEW 102
  • 8.2 BIOACTIVE LIPIDS 105
    • 8.2.1 PLANT LIPIDS 106
    • 8.2.2 LIPID ACTIVATORS 106
    • 8.2.3 LIPID INHIBITORS 106
    • 8.2.4 AGONISTS 106
    • 8.2.5 BIOACTIVE CERAMIDES 106
    • 8.2.6 ACYL CARNITINE LIPIDS 106
    • 8.2.7 ENDOCANNABINOIDS 107
    • 8.2.8 LIPO-NUCLEOTIDES 107
    • 8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL 107
    • 8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP) 107
  • 8.3 POLYMERIZABLE LIPIDS 107
    • 8.3.1 FUNCTIONAL PEG LIPIDS 108
    • 8.3.2 MPEG STEROLS 108
    • 8.3.3 MPEG CERAMIDES 108
    • 8.3.4 MPEG PHOSPHOLIPIDS 108
    • 8.3.5 MPEG GLYCERIDES 108
  • 8.4 FLUORESCENT LIPIDS 109
    • 8.4.1 FLUORESCENT SPHINGOLIPIDS 110
    • 8.4.2 FLUORESCENT GLYCEROLIPIDS 110
    • 8.4.3 FLUORESCENT PEG LIPIDS 110
    • 8.4.4 FLUORESCENT PHOSPHOLIPIDS 110
    • 8.4.5 FLUORESCENT STEROLS 110
    • 8.4.6 OTHERS 110
  • 8.5 BACTERIAL LIPIDS 111
    • 8.5.1 MYCOLIC LIPIDS 112
    • 8.5.2 N-ACYLHOMOSERINE LIPIDS 112
    • 8.5.3 BRANCHED LIPIDS 112
    • 8.5.4 CYCLOPROPYL LIPIDS 112
  • 8.6 NEUTRAL LIPIDS 112
    • 8.6.1 PRENOLS 113
    • 8.6.2 VERY LONG CHAIN FATTY ACIDS 113
    • 8.6.3 GLYCERIDES 113
    • 8.6.4 EICSANOIDS 113
    • 8.6.5 OXYGENATED FATTY ACIDS 113
    • 8.6.6 GLYCOSYLATED DIACYL GLYCEROLS 113
    • 8.6.7 PROSTAGLANDINS 113
  • 8.7 HEADGROUP MODIFIED LIPIDS 114
    • 8.7.1 FUNCTIONAL LIPIDS 115
    • 8.7.2 ANTIGENIC LIPIDS 115
    • 8.7.3 GLYCOSYLATED LIPIDS 115
    • 8.7.4 CHELATORS 115
    • 8.7.5 ADHESIVE LIPIDS 115
    • 8.7.6 SNAP-TAG REACTING LIPIDS 115
    • 8.7.7 ALKYL PHOSPHATES 115
  • 8.8 OTHERS 116

9 GLOBAL LIPIDS MARKET, BY DELIVERY SYSTEMS 117

  • 9.1 OVERVIEW 118
  • 9.2 LIPOSOMES 121
    • 9.2.1 LIPOSOMES FOR DNA/RNA 122
      • 9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY 122
      • 9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY 122
      • 9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY 122
      • 9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY 122
      • 9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY 123
      • 9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY 123
    • 9.2.2 REACTIVE LIPOSOMES 123
      • 9.2.2.1 SUCCINYL LIPOSOMES 123
      • 9.2.2.2 DBCO LIPOSOMES 123
      • 9.2.2.3 BIOTINYLATED LIPOSOMES 124
      • 9.2.2.4 CARBOXYLIC ACID LIPOSOMES 124
      • 9.2.2.5 AMINE LIPOSOMES 124
      • 9.2.2.6 CYANUR LIPOSOMES 124
      • 9.2.2.7 AZIDE LIPOSOMES 124
      • 9.2.2.8 FOLATE LIPOSOMES 124
      • 9.2.2.9 DODECANYL LIPOSOMES 124
      • 9.2.2.10 NI REACTIVE LIPOSOMES 124
      • 9.2.2.11 PDP LIPOSOMES 124
      • 9.2.2.12 GLUTARYL LIPOSOMES 124
      • 9.2.2.13 OTHERS 124
    • 9.2.3 DRUG LOADED LIPOSOMES 125
    • 9.2.4 PLAIN LIPOSOMES 125
      • 9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES 125
      • 9.2.4.2 DOTAP LIPOSOMES 125
      • 9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES 125
      • 9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES 125
      • 9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES 125
      • 9.2.4.6 OTHERS 126
  • 9.3 SOLID LIPID NANOPARTICLES 126
  • 9.4 NANOSTRUCTURES LIPID CARRIER 127
  • 9.5 TRANSFEROSOMES 128
  • 9.6 NIOSOMES 129
  • 9.7 OTHERS 130

10 GLOBAL LIPIDS MARKET, BY SOURCE 131

  • 10.1 OVERVIEW 132
  • 10.2 PURIFIED FATTY ACIDS 135
  • 10.3 PURIFIED OILS 136
  • 10.4 EGG YOLK 137
  • 10.5 SOYABEAN 138
  • 10.6 NON-GMO SOYABEAN 139
  • 10.7 OTHERS 140

11 GLOBAL LIPIDS MARKET, BY END USER 141

  • 11.1 OVERVIEW 142
  • 11.2 PHARMACEUTICAL INDUSTRIES 145
  • 11.3 BIOTECHNOLOGY INDUSTRIES 146
  • 11.4 COSMETIC INDUSTRIES 147
  • 11.5 ACADEMIC AND RESEARCH INSTITUTES 147
  • 11.6 OTHERS 148

12 GLOBAL LIPIDS MARKET, BY DISTRIBUTION CHANNEL 149

  • 12.1 OVERVIEW 150
  • 12.2 DIRECT TENDER 153
  • 12.3 RETAIL SALES 154
  • 12.4 OTHERS 155

13 GLOBAL LIPIDS MARKET, BY REGION 156

  • 13.1 OVERVIEW 157
  • 13.2 NORTH AMERICA 163
    • 13.2.1 U.S. 175
    • 13.2.2 CANADA 182
    • 13.2.3 MEXICO 189
  • 13.3 EUROPE 196
    • 13.3.1 GERMANY 208
    • 13.3.2 U.K. 215
    • 13.3.3 ITALY 222
    • 13.3.4 SPAIN 229
    • 13.3.5 FRANCE 236
    • 13.3.6 SWITZERLAND 243
    • 13.3.7 BELGIUM 250
    • 13.3.8 NETHERLANDS 257
    • 13.3.9 RUSSIA 264
    • 13.3.10 TURKEY 271
    • 13.3.11 REST OF EUROPE 278
  • 13.4 ASIA-PACIFIC 279
    • 13.4.1 CHINA 291
    • 13.4.2 JAPAN 298
    • 13.4.3 SOUTH KOREA 305
    • 13.4.4 INDIA 312
    • 13.4.5 AUSTRALIA 319
    • 13.4.6 SINGAPORE 326
    • 13.4.7 THAILAND 333
    • 13.4.8 MALAYSIA 340
    • 13.4.9 INDONESIA 347
    • 13.4.10 PHILIPPINES 354
    • 13.4.11 REST OF ASIA PACIFIC 361
  • 13.5 SOUTH AMERICA 362
    • 13.5.1 BRAZIL 374
    • 13.5.2 ARGENTINA 381
    • 13.5.3 REST OF SOUTH AFRICA 388
  • 13.6 MIDDLE EAST AND AFRICA 389
    • 13.6.1 SOUTH AFRICA 401
    • 13.6.2 SAUDI ARABIA 408
    • 13.6.3 U.A.E. 415
    • 13.6.4 EGYPT 422
    • 13.6.5 ISRAEL 429
    • 13.6.6 REST OF MIDDLE EAST AND AFRICA 436

14 GLOBAL LIPIDS MARKET: COMPANY LANDSCAPE 437

  • 14.1 COMPANY SHARE ANALYSIS: GLOBAL 437
  • 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 438
  • 14.3 COMPANY SHARE ANALYSIS: EUROPE 439
  • 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 440

15 SWOT ANALYSIS 441

16 COMPANY PROFILE 442

  • 16.1 BIONTECH SE. 442
    • 16.1.1 COMPANY SNAPSHOT 442
    • 16.1.2 REVENUE ANALYSIS 443
    • 16.1.3 COMPANY SHARE ANALYSIS 443
    • 16.1.4 PRODUCT PORTFOLIO 443
    • 16.1.5 RECENT DEVELOPMENT 444
  • 16.2 MODERNA, INC. 445
    • 16.2.1 COMPANY SNAPSHOT 445
    • 16.2.2 REVENUE ANALYSIS 445
    • 16.2.3 COMPANY SHARE ANALYSIS 446
    • 16.2.4 PRODUCT PORTFOLIO 446
    • 16.2.5 RECENT DEVELOPMENTS 446
  • 16.3 PFIZER INC. 447
    • 16.3.1 COMPANY SNAPSHOT 447
    • 16.3.2 REVENUE ANALYSIS 447
    • 16.3.3 COMPANY SHARE ANALYSIS 448
    • 16.3.4 PRODUCT PORTFOLIO 448
    • 16.3.5 RECENT DEVELOPMENTS 448
  • 16.4 CARGILL, INCORPORATED. 449
    • 16.4.1 COMPANY SNAPSHOT 449
    • 16.4.2 COMPANY SHARE ANALYSIS 449
    • 16.4.3 PRODUCT PORTFOLIO 449
    • 16.4.4 RECENT DEVELOPMENTS 449
  • 16.5 KERRY. 450
    • 16.5.1 COMPANY SNAPSHOT 450
    • 16.5.2 COMPANY SHARE ANALYSIS 450
    • 16.5.3 PRODUCT PORTFOLIO 451
    • 16.5.4 RECENT DEVELOPMENTS 451
  • 16.6 ABITEC 452
    • 16.6.1 COMPANY SNAPSHOT 452
    • 16.6.2 PRODUCT PORTFOLIO 452
    • 16.6.3 RECENT DEVELOPMENTS 452
  • 16.7 ADMSIO 454
    • 16.7.1 COMPANY SNAPSHOT 454
    • 16.7.2 PRODUCT PORTFOLIO 454
    • 16.7.3 RECENT DEVELOPMENTS 454
  • 16.8 ALNYLAM PHARMACEUTICALS, INC. 455
    • 16.8.1 COMPANY SNAPSHOT 455
    • 16.8.2 REVENUE ANALYSIS 455
    • 16.8.3 PRODUCT PORTFOLIO 456
    • 16.8.4 RECENT DEVELOPMENT 456
  • 16.9 BASF SE 457
    • 16.9.1 COMPANY SNAPSHOT 457
    • 16.9.2 REVENUE ANALYSIS 458
    • 16.9.3 PRODUCT PORTFOLIO 458
    • 16.9.4 RECENT DEVELOPMENTS 458
  • 16.10 CAYMAN CHEMICAL 459
    • 16.10.1 COMPANY SNAPSHOT 459
    • 16.10.2 PRODUCT PORTFOLIO 459
    • 16.10.3 RECENT DEVELOPMENTS 459
  • 16.11 CD BIOPARTCLES. 460
    • 16.11.1 COMPANY SNAPSHOT 460
    • 16.11.2 PRODUCT PORTFOLIO 460
    • 16.11.3 RECENT DEVELOPMENTS 460
  • 16.12 CHEMI S.P.A. 461
    • 16.12.1 COMPANY SNAPSHOT 461
    • 16.12.2 PRODUCT PORTFOLIO 461
    • 16.12.3 RECENT DEVELOPMENTS 461
  • 16.13 CORDENPHARMA INTERNATIONAL 462
    • 16.13.1 COMPANY SNAPSHOT 462
    • 16.13.2 PRODUCT PORTFOLIO 462
    • 16.13.3 RECENT DEVELOPMENTS 462
  • 16.14 CRODA INTERNATIONAL PLC. 464
    • 16.14.1 COMPANY SNAPSHOT 464
    • 16.14.2 PRODUCT PORTFOLIO 464
    • 16.14.3 RECENT DEVELOPMENTS 464
  • 16.15 CURIA GLOBAL, INC. 465
    • 16.15.1 COMPANY SNAPSHOT 465
    • 16.15.2 PRODUCT PORTFOLIO 465
    • 16.15.3 RECENT DEVELOPMENT 465
  • 16.16 DSM 467
    • 16.16.1 COMPANY SNAPSHOT 467
    • 16.16.2 PRODUCT PORTFOLIO 467
    • 16.16.3 RECENT DEVELOPMENTS 467
  • 16.17 EVONIK INDUSTRIES AG 468
    • 16.17.1 COMPANY SNAPSHOT 468
    • 16.17.2 PRODUCT PORTFOLIO 468
    • 16.17.3 RECENT DEVELOPMENTS 468
  • 16.18 GATTEFOSSE 470
    • 16.18.1 COMPANY SNAPSHOT 470
    • 16.18.2 PRODUCT PORTFOLIO 470
    • 16.18.3 RECENT DEVELOPMENTS 470
  • 16.19 LIPOID GMBH 471
    • 16.19.1 COMPANY SNAPSHOT 471
    • 16.19.2 PRODUCT PORTFOLIO 471
    • 16.19.3 RECENT DEVELOPMENT 472
  • 16.20 MATREYA, LLC 473
    • 16.20.1 COMPANY SNAPSHOT 473
    • 16.20.2 PRODUCT PORTFOLIO 473
    • 16.20.3 RECENT DEVELOPMENTS 473
  • 16.21 MERCK KGAA 474
    • 16.21.1 COMPANY SNAPSHOT 474
    • 16.21.2 PRODUCT PORTFOLIO 474
    • 16.21.3 RECENT DEVELOPMENTS 474
  • 16.22 NOF EUROPE GMBH 475
    • 16.22.1 COMPANY SNAPSHOT 475
    • 16.22.2 PRODUCT PORTFOLIO 475
    • 16.22.3 RECENT DEVELOPMENTS 475
  • 16.23 STEPAN COMPANY 476
    • 16.23.1 COMPANY SNAPSHOT 476
    • 16.23.2 PRODUCT PORTFOLIO 476
    • 16.23.3 RECENT DEVELOPMENTS 476
  • 16.24 TOKYO CHEMICAL INDUSTRY CO., LTD. 478
    • 16.24.1 COMPANY SNAPSHOT 478
    • 16.24.2 PRODUCT PORTFOLIO 478
    • 16.24.3 RECENT DEVELOPMENTS 478
  • 16.25 VAV LIFE SCIENCES PVT LTD 479
    • 16.25.1 COMPANY SNAPSHOT 479
    • 16.25.2 PRODUCT PORTFOLIO 479
    • 16.25.3 RECENT DEVELOPMENTS 479

17 QUESTIONNAIRE 480

18 RELATED REPORTS 484

LIST OF FIGURES

  • FIGURE 1 GLOBAL LIPIDS MARKET: SEGMENTATION 51
  • FIGURE 2 GLOBAL LIPIDS MARKET: DATA TRIANGULATION 54
  • FIGURE 3 GLOBAL LIPIDS MARKET: DROC ANALYSIS 55
  • FIGURE 4 GLOBAL LIPIDS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 56
  • FIGURE 5 GLOBAL LIPIDS MARKET: COMPANY RESEARCH ANALYSIS 56
  • FIGURE 6 GLOBAL LIPIDS MARKET: INTERVIEW DEMOGRAPHICS 58
  • FIGURE 7 GLOBAL LIPIDS MARKET: DBMR MARKET POSITION GRID 59
  • FIGURE 8 GLOBAL LIPIDS MARKET: MARKET END USER COVERAGE GRID 60
  • FIGURE 9 GLOBAL LIPIDS MARKET: VENDOR SHARE ANALYSIS 61
  • FIGURE 10 GLOBAL LIPIDS MARKET: SEGMENTATION 65
  • FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE GLOBAL LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 66
  • FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LIPIDS MARKET IN 2023 & 2030 66
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LIPIDS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 67
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR LIPIDS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 68
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL LIPIDS MARKET 88
  • FIGURE 16 GLOBAL LIPIDS MARKET: BY TYPE, 2022 95
  • FIGURE 17 GLOBAL LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION) 96
  • FIGURE 18 GLOBAL LIPIDS MARKET: BY TYPE, CAGR (2023-2030) 96
  • FIGURE 19 GLOBAL LIPIDS MARKET: BY TYPE, LIFELINE CURVE 97
  • FIGURE 20 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, 2022 102
  • FIGURE 21 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION) 103
  • FIGURE 22 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030) 103
  • FIGURE 23 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE 104
  • FIGURE 24 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022 118
  • FIGURE 25 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION) 119
  • FIGURE 26 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030) 119
  • FIGURE 27 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE 120
  • FIGURE 28 GLOBAL LIPIDS MARKET: BY SOURCE, 2022 132
  • FIGURE 29 GLOBAL LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION) 133
  • FIGURE 30 GLOBAL LIPIDS MARKET: BY SOURCE, CAGR (2023-2030) 133
  • FIGURE 31 GLOBAL LIPIDS MARKET: BY SOURCE, LIFELINE CURVE 134
  • FIGURE 32 GLOBAL LIPIDS MARKET: BY END USER, 2022 142
  • FIGURE 33 GLOBAL LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION) 143
  • FIGURE 34 GLOBAL LIPIDS MARKET: BY END USER, CAGR (2023-2030) 143
  • FIGURE 35 GLOBAL LIPIDS MARKET: BY END USER, LIFELINE CURVE 144
  • FIGURE 36 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022 150
  • FIGURE 37 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 151
  • FIGURE 38 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 151
  • FIGURE 39 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 152
  • FIGURE 40 GLOBAL LIPIDS MARKET: SNAPSHOT (2022) 158
  • FIGURE 41 GLOBAL LIPIDS MARKET: BY REGION (2022) 160
  • FIGURE 42 GLOBAL LIPIDS MARKET: BY REGION (2023 & 2030) 160
  • FIGURE 43 GLOBAL LIPIDS MARKET: BY REGION (2022 & 2030) 161
  • FIGURE 44 GLOBAL LIPIDS MARKET: BY TYPE (2023-2030) 161
  • FIGURE 45 NORTH AMERICA LIPIDS MARKET: SNAPSHOT (2022) 164
  • FIGURE 46 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022) 166
  • FIGURE 47 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2023 & 2030) 166
  • FIGURE 48 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022 & 2030) 167
  • FIGURE 49 NORTH AMERICA LIPIDS MARKET: BY TYPE (2023 & 2030) 167
  • FIGURE 50 EUROPE LIPIDS MARKET: SNAPSHOT (2022) 197
  • FIGURE 51 EUROPE LIPIDS MARKET: BY COUNTRY (2022) 199
  • FIGURE 52 EUROPE LIPIDS MARKET: BY COUNTRY (2023 & 2030) 199
  • FIGURE 53 EUROPE LIPIDS MARKET: BY COUNTRY (2022 & 2030) 200
  • FIGURE 54 EUROPE LIPIDS MARKET: BY TYPE (2023 & 2030) 200
  • FIGURE 55 ASIA-PACIFIC LIPIDS MARKET: SNAPSHOT (2022) 280
  • FIGURE 56 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2022) 282
  • FIGURE 57 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2023 & 2030) 282
  • FIGURE 58 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2022 & 2030) 283
  • FIGURE 59 ASIA-PACIFIC LIPIDS MARKET: BY TYPE (2023 & 2030) 283
  • FIGURE 60 SOUTH AMERICA LIPIDS MARKET: SNAPSHOT (2022) 363
  • FIGURE 61 SOUTH AMERICA LIPIDS MARKET: BY COUNTRY (2022) 365
  • FIGURE 62 SOUTH AMERICA LIPIDS MARKET: BY COUNTRY (2023 & 2030) 365
  • FIGURE 63 SOUTH AMERICA LIPIDS MARKET: BY COUNTRY (2022 & 2030) 366
  • FIGURE 64 SOUTH AMERICA LIPIDS MARKET: BY TYPE (2023 & 2030) 366
  • FIGURE 65 MIDDLE EAST AND AFRICA LIPIDS MARKET: SNAPSHOT (2022) 390
  • FIGURE 66 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022) 392
  • FIGURE 67 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2023 & 2030) 392
  • FIGURE 68 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022 & 2030) 393
  • FIGURE 69 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY TYPE (2023 & 2030) 393
  • FIGURE 70 GLOBAL LIPIDS MARKET: COMPANY SHARE 2022 (%) 437
  • FIGURE 71 NORTH AMERICA LIPIDS MARKET: COMPANY SHARE 2022 (%) 438
  • FIGURE 72 EUROPE LIPIDS MARKET: COMPANY SHARE 2022 (%) 439
  • FIGURE 73 ASIA-PACIFIC LIPIDS MARKET: COMPANY SHARE 2022 (%) 440